Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.
Bailey BL, Nguyen W, Ngo A, Goodman CD, Gancheva MR, Favuzza P, Sanz LM, Gamo FJ, Lowes KN, McFadden GI, Wilson DW, Laleu B, Brand S, Jackson PF, Cowman AF, Sleebs BE